Targeting Survivin with YM155 (Sepantronium Bromide): A novel therapeutic strategy for paediatric acute myeloid leukaemia

These data suggest that YM155-mediated inhibition of Survivin is a potentially beneficial therapeutic strategy for AML, particularly paediatric disease, and warrants further evaluation.